Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ticagrelor

FDA-approved product (tablet, oral), marketed as Brilinta, Ticagrelor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ticagrelor
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Acute myocardial infarction
  • Coronary artery disease
  • Myocardial infarction
  • Peripheral vascular disease
  • Recurrent thrombophlebitis
  • Stroke
  • Thrombotic disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
P2Y12 Platelet Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ticagrelor in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ticagrelor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Canadian Ticagrelor Survey

    NCT01757483 · start 2012-11

    Registered record
    Registry ID
    NCT01757483
    Conditions
    Acute Coronary Syndrome
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-12
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

    NCT01642966 · start 2012-09

    Registered record
    Registry ID
    NCT01642966
    Conditions
    Acute Coronary Syndrome
    Interventions
    Prasugrel; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-09
    Completion
    2012-09
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionPrasugrel; Ticagrelor
    PhasePhase 4
    Registry statusCompleted

  • PROMUS Element Plus US Post-Approval Study

    NCT01589978 · start 2012-05

    Registered record
    Registry ID
    NCT01589978
    Conditions
    Coronary Artery Disease
    Interventions
    PROMUS Element Plus Coronary Stent System; Aspirin; P2Y12 antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-05
    Completion
    2018-06
    Enrolment
    2,681

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionPROMUS Element Plus Coronary Stent System; Aspirin; P2Y12 antagonist
    PhasePhase 4
    Registry statusCompleted

  • Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

    NCT01587651 · start 2012-03

    Registered record
    Registry ID
    NCT01587651
    Conditions
    Coronary Artery Disease
    Interventions
    Prasugrel Loading Dose; Prasugrel Maintenance Dose; Ticagrelor Maintenance Dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-02
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionPrasugrel Loading Dose; Prasugrel Maintenance Dose; Ticagrelor Maintenance Dose
    PhasePhase 4
    Registry statusCompleted

  • Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)

    NCT01761786 · start 2011-06

    Registered record
    Registry ID
    NCT01761786
    Conditions
    Myocardial Infarction; STEMI
    Interventions
    CYP2C19 genotyping
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-06
    Completion
    2019-04-04
    Enrolment
    2,700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; STEMI
    InterventionCYP2C19 genotyping
    PhasePhase 4
    Registry statusCompleted